Humanized mouse models for assessing immune cell therapy
US12196744B2 · kind B2 · utility
0Cited by
4References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 2022 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Mar 25, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are humanized mouse models and methods for determining whether administration of engineered immune cell therapies likely elicit cytokine release syndrome and/or determining the efficacy of an anti-disease therapy. Further, the models provided herein may be used to test the efficacy of different anti-CRS therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.